###begin article-title 0
###xml 47 53 <span type="species:ncbi:9606">Humans</span>
SLC2A9 Is a High-Capacity Urate Transporter in Humans
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 26 32 <span type="species:ncbi:9606">humans</span>
###xml 678 681 <span type="species:ncbi:9606">man</span>
Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have found common genetic variants of SLC2A9 to be associated with increased serum urate level and gout. The SLC2A9 gene encodes a facilitative glucose transporter, and it has two splice variants that are highly expressed in the proximal nephron, a key site for urate handling in the kidney. We investigated whether SLC2A9 is a functional urate transporter that contributes to the longstanding association between urate and blood pressure in man.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 44 58 44 58 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Xenopus laevis</named-content>
###xml 627 628 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 628 629 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 947 953 945 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1056 1062 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1152 1158 1150 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1307 1308 1305 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1340 1346 1338 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1526 1532 1524 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1595 1596 1593 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1682 1683 1680 1681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 44 58 <span type="species:ncbi:8355">Xenopus laevis</span>
###xml 707 712 <span type="species:ncbi:9606">human</span>
###xml 1017 1020 <span type="species:ncbi:9606">men</span>
###xml 1400 1412 <span type="species:ncbi:9606">participants</span>
###xml 1486 1498 <span type="species:ncbi:9606">participants</span>
We expressed both SLC2A9 splice variants in Xenopus laevis oocytes and found both isoforms mediate rapid urate fluxes at concentration ranges similar to physiological serum levels (200-500 muM). Because SLC2A9 is a known facilitative glucose transporter, we also tested whether glucose or fructose influenced urate transport. We found that urate is transported by SLC2A9 at rates 45- to 60-fold faster than glucose, and demonstrated that SLC2A9-mediated urate transport is facilitated by glucose and, to a lesser extent, fructose. In addition, transport is inhibited by the uricosuric benzbromarone in a dose-dependent manner (Ki = 27 muM). Furthermore, we found urate uptake was at least 2-fold greater in human embryonic kidney (HEK) cells overexpressing SLC2A9 splice variants than nontransfected kidney cells. To confirm that our findings were due to SLC2A9, and not another urate transporter, we showed that urate transport was diminished by SLC2A9-targeted siRNA in a second mammalian cell line. In a cohort of men we showed that genetic variants of SLC2A9 are associated with reduced urinary urate clearance, which fits with common variation at SLC2A9 leading to increased serum urate. We found no evidence of association with hypertension (odds ratio 0.98, 95% confidence interval [CI] 0.9 to 1.05, p > 0.33) by meta-analysis of an SLC2A9 variant in six case-control studies including 11,897 participants. In a separate meta-analysis of four population studies including 11,629 participants we found no association of SLC2A9 with systolic (effect size -0.12 mm Hg, 95% CI -0.68 to 0.43, p = 0.664) or diastolic blood pressure (effect size -0.03 mm Hg, 95% CI -0.39 to 0.31, p = 0.82).
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
This study provides evidence that SLC2A9 splice variants act as high-capacity urate transporters and is one of the first functional characterisations of findings from genome-wide association scans. We did not find an association of the SLC2A9 gene with blood pressure in this study. Our findings suggest potential pathogenic mechanisms that could offer a new drug target for gout.
###end p 6
###begin title 7
Editors' Summary
###end title 7
###begin title 8
Background.
###end title 8
###begin p 9
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 243 249 <span type="species:ncbi:9606">people</span>
###xml 369 375 <span type="species:ncbi:9606">people</span>
###xml 481 487 <span type="species:ncbi:9606">people</span>
Blood is continually pumped around the human body to deliver the chemicals needed to keep the body's cells alive and to take cellular waste products to the kidneys where they are filtered out of the blood and excreted in the urine. In healthy people, the levels of nutrients and waste products in serum (the liquid part of blood) fall within "normal" ranges but in ill people these levels can be very different. For example, serum uric acid (urate) levels are usually increased in people with gout. In this arthritic condition, uric acid crystallizes in the joints (often those in the big toe) and causes swelling and intense pain. Increased serum urate levels, which are also associated with high blood pressure, diabetes, and several other important conditions, can be caused by eating food that is rich in chemicals called purines (for example, liver, dried beans, and port). The body also converts its own purines into uric acid so genetic variations in the enzymes involved in purine breakdown can alter serum urate levels, as can variations in the rate of urate removal from the body by the kidneys. Urinary urate excretion is controlled by urate transporters, proteins that carry urate into and out of the kidney cells. Uricosuric drugs, which are used to treat gout, reduce serum urate levels by inhibiting a urate transporter that reabsorbs urate from urine.
###end p 9
###begin title 10
Why Was This Study Done?
###end title 10
###begin p 11
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 178 183 <span type="species:ncbi:9606">human</span>
###xml 222 228 <span type="species:ncbi:9606">people</span>
###xml 266 272 <span type="species:ncbi:9606">people</span>
Several urate transporters have already been identified but recently, using an approach called genome-wide association scanning, scientists found that some genetic variants of a human gene called SLC2A9 are more common in people with high serum urate levels than in people with normal levels. SLC2A9 encodes a glucose transporter (a protein that helps to move the sugar glucose through cell membranes) and is highly expressed in the kidney's main urate handling site. Given these facts, could SLC2A9 (the protein made from SLC2A9) be a urate transporter as well as a glucose transporter? In this study, the researchers investigate this possibility and also ask whether genetic variations in SLC2A9 might be responsible for the association between serum urate levels and high blood pressure.
###end p 11
###begin title 12
What Did the Researchers Do and Find?
###end title 12
###begin p 13
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1138 1144 1138 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:10090">mouse</span>
###xml 556 561 <span type="species:ncbi:10090">mouse</span>
###xml 781 784 <span type="species:ncbi:9606">men</span>
###xml 1250 1262 <span type="species:ncbi:9606">participants</span>
The researchers first expressed SLC2A9 in frog eggs, a type of cell that does not have its own urate transporter. They found that urate rapidly moved into eggs expressing SLC2A9 but not into control eggs, that SLC2A9 transported urate about 50 times faster than glucose, and that glucose stimulated SLC2A9-mediated urate transport. Similarly, overexpression of SLC2A9 in human embryonic kidney cells more than doubled their urate uptake. Conversely, when the researchers used a technique called RNA interference to reduce the expression of mouse SLC2A9 in mouse cells that normally makes this protein, urate transport was reduced. Next, the researchers looked at two small parts of SLC2A9 that vary between individuals (so-called single polynucleotide polymorphisms) in nearly 900 men who had had their serum urate levels and urinary urate excretion rates measured. They found that certain genetic variations at these two sites were associated with increased serum urate levels and decreased urinary urate excretion. Finally, the researchers used a statistical technique called meta-analysis to look for an association between one of the SLC2A9 gene variants and blood pressure. In two separate meta-analyses that together involved more than 20, 000 participants in several studies, there was no association between this gene variant and blood pressure.
###end p 13
###begin title 14
What Do These Findings Mean?
###end title 14
###begin p 15
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Overall, these findings indicate that SLCA9 is a high capacity urate transporter and suggest that this protein plays an important part in controlling serum urate levels. They provide confirmation that common genetic variants in SLC2A9 affect serum urate levels to a marked degree, although they do not show exactly which genetic variant is responsible for increasing serum urate levels. They also provide important new insights into how the kidneys normally handle urate and suggest ways in which this essential process may sometimes go wrong. Thus, these findings could eventually lead to new treatments for gout and possibly for other diseases that are associated with increased serum urate levels.
###end p 15
###begin title 16
Additional Information.
###end title 16
###begin p 17
Please access these Web sites via the online version of this summary at .
###end p 17
###begin p 18
###xml 92 100 <span type="species:ncbi:9606">patients</span>
The UK National Health Service Direct health encyclopedia provides detailed information for patients about 
###end p 18
###begin p 19
 provides links to many sources of information about gout (in English and Spanish), including , an easy-to-read guide from the US National Institutes of Arthritis and Musculoskeletal and Skin Diseases
###end p 19
###begin p 20
Wikipedia also has pages on , , and  (note: Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 20
###begin p 21
The  also has information on gout
###end p 21
###begin p 22
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Mark Caulfield and colleagues show that theSLC2A9 gene, which encodes a facilitative glucose transporter, is also a high-capacity urate transporter.
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b001">1</xref>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b004">4</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b005">5</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b005">5</xref>
###xml 904 905 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b005">5</xref>
###xml 268 274 <span type="species:ncbi:9606">Humans</span>
###xml 285 289 <span type="species:ncbi:4456">apes</span>
###xml 409 415 <span type="species:ncbi:9606">humans</span>
Elevated serum urate levels are associated with important common disorders such as gout, metabolic syndrome, diabetes, hypertension, and cardiovascular morbidity and mortality [1-4]. Uric acid is principally derived from the breakdown of dietary and cellular purines. Humans and great apes are exposed to higher urate levels than other mammalian species because of the inactivation of hepatic uricase [5]. In humans the kidney has a pivotal role in urate handling, with secretory mechanisms balanced against efficient reabsorption resulting in only 10% of the filtered load actually being excreted in the urine [5]. The established urate transporter systems in the proximal nephron includes; the urate anion transporter (URAT1), which is a target of uricosuric drugs, multiple organic anion transporters (OATs 1-4), the urate transporter (UAT), and a voltage dependent organic anion transporter (OATv1) [5].
###end p 24
###begin p 25
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b001">1</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b005">5</xref>
###xml 415 421 415 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b006">6</xref>
###xml 461 462 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b007">7</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b009">9</xref>
###xml 758 759 758 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 921 927 921 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
It is possible that genetic variation in either enzymatic breakdown of purines or renal transporters of uric acid might elevate serum levels and account for the long-standing association with blood pressure and common cardiovascular phenotypes [1-5]. Recently, two separate genome-wide association scans identified and replicated association of serum urate level with common variants within the glucose transporter SLC2A9 (GLUT9) gene region on Chromosome 4 [6,7]. Interestingly, this member of the facilitative glucose transporter family has two splice variants most strongly expressed in the apical and basolateral membranes of the proximal tubular epithelial cells of the kidney [8,9]. SLC2A9 is not as efficient a glucose transporter as GLUT1 and GLUT4 [8], so we set out to test whether SLC2A9a and SLC2A9b splice variants act as urate transporters. We used data from the Olivetti Heart Study to test association of SLC2A9 variants and fractional urate excretion, and then tested for association with blood pressure and hypertension in additional cohorts.
###end p 25
###begin title 26
Methods
###end title 26
###begin title 27
Reagents and Antibodies
###end title 27
###begin p 28
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 180 187 <span type="species:ncbi:9986">rabbits</span>
###xml 457 462 <span type="species:ncbi:10090">mouse</span>
###xml 490 497 <span type="species:ncbi:9986">rabbits</span>
All chemicals were obtained from Sigma-Aldrich unless otherwise noted. Two polyclonal antibodies against N-terminal peptides of both splice variants of human SLC2A9 were raised in rabbits (Rockland Immunochemicals). The SLC2A9a antibody was raised against DTSHARPPGPGRALLEC and the SLC2A9b was raised against KSRGEDEESDSAKKC. Both antibodies were peptide purified before use. Two polyclonal antibodies against N-terminal peptides of both splice variants of mouse SLC2A9 were also raised in rabbits (Rockland Immunochemicals). The mSLC2A9a antibody was raised against MDSRELALASLMC and the mSLC2A9b antibody was raised against MKLSEKNSAETKESC, and both antibodies were peptide purified before use.
###end p 28
###begin title 29
###xml 21 35 21 35 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Xenopus laevis</named-content>
###xml 21 35 <span type="species:ncbi:8355">Xenopus laevis</span>
mRNA Preparation and Xenopus laevis Oocyte Microinjection
###end title 29
###begin p 30
###xml 194 203 194 203 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">X. laevis</named-content>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b009">9</xref>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 194 203 <span type="species:ncbi:8355">X. laevis</span>
Plasmids containing genes encoding the wild-type human SLC2A9a or SLC2A9b isoform were linearized with Nhe I and transcribed in vitro with T7 polymerase mMESSAGE mMACHINE (Ambion). Adult female X. laevis oocytes (prepared as described in [9]) were injected with 20 nl (1 ng/nl) SLC2A9a or SLC2A9b synthetic mRNA transcript and incubated for 5 d at 16-18 degreesC prior to functional uptake assays. The concentration of RNA prior to injection was determined using Bio-Rad SmartSpec 3000 machine.
###end p 30
###begin title 31
Determination of Functional Activity by Radiotracer Flux Assays
###end title 31
###begin p 32
###xml 96 98 90 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
The influx experiments were performed at 22 degreesC using 10-12 oocytes for each condition and 14C-labelled urate at a specific activity of 54 mCi/mmole, 250 muCi/ml. Oocytes were washed with ice-cold modified Barth's medium (MBM) to stop the uptake, and then individual oocytes were placed in vials and dissolved in 0.5 ml of 5% SDS for 30 min. Finally, scintillation fluid (5 ml) was added to each vial and radioactivity measured using a Beckman LS6500 liquid scintillation counter. All experiments were performed three to six times and the results were corrected for the flux values obtained with non-injected oocytes obtained from the same frog.
###end p 32
###begin p 33
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 624 625 617 618 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 635 636 628 629 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 661 662 654 655 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
Efflux experiments were performed by injecting oocytes with 40 nl of 14C-urate just prior to the flux measurements. Eggs were then incubated in batches of 20 in 1 ml of medium for 20 min at 22 degreesC. Samples of 20 mul of incubation medium were taken every 2 min to measure the appearance of urate in the outside solution. The incubation volume was kept constant by sequential addition of medium after the removal of each sample. The activity remaining in the eggs at the end of the incubation was measured by solubilising the oocytes in 1 ml of 5% SDS overnight. Incubation medium consisted of MBM supplemented with 5 mM d-glucose, d-fructose, uric acid, or l-glucose (control). Efflux data were then plotted as a function of the fraction of total urate remaining in the eggs at each incubation time point. This was expressed as the log (remaining urate/initial injected urate x 100) for the SLC2A9a-expressing eggs. Net SLC2A9a-mediated efflux was determined by subtracting urate efflux observed in non-injected oocytes from total urate efflux from SLC2A9a oocytes at each time point.
###end p 33
###begin title 34
Thin-Layer Chromatography
###end title 34
###begin p 35
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 91 93 91 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 534 535 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 535 536 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sub>
To determine if urate was metabolized within the Xenopus oocytes we microinjected 40 nl of 14C- labelled 2 mM urate and collected the efflux medium from both water-injected eggs and those expressing SLC2A9a. We then loaded 100 mul of the efflux media onto a silica-coated glass chromatography plate and eluted with a 80:15:5 n-propanol:ammonium hydroxide (25%):water solution. Standard urate and allantoin solutions were used for comparison. After drying the plate, a vanillin spray was used to visualize the urate and allantoin. The Rf value (distance travelled from solvent front) for urate was 0.0103 and that for allantoin 0.238.
###end p 35
###begin title 36
Kinetic Analysis
###end title 36
###begin p 37
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b010">10</xref>
Urate transport into oocytes expressing SLC2A9a or SLC2A9b was measured over a range of concentrations from 0.001 to 2 mM using 20 min incubations, which had been determined to be within the linear component of uptake. Uptake was corrected for nonspecific entry using non-mRNA injected eggs from the same batch in each experiment. SIGMAPLOT 6 software was used to determine the transport kinetics for the SLC2A9 mediated urate uptake by nonlinear regression analysis. The analysis assumed standard simple Michaelis-Menten kinetics for a facilitative transporter with no cooperativity. In addition to the regression analysis, an Eadie-Hofstee linear transformation was included, the results of which could imply that a more complex kinetic model is required to fully describe the characteristics of this transporter. Inhibitors were used at concentrations similar to previous studies of other glucose or urate transporters, e.g., phloretin, benzbromarone, and furosemide, and which corresponded with effective pharmacological doses, e.g., probenecid [10].
###end p 37
###begin title 38
HEK293 Cells and Urate Uptake
###end title 38
###begin p 39
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 755 757 730 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 42 47 <span type="species:ncbi:9606">human</span>
HEK293 cells were stably transfected with human SLC2A9a or SLC2A9b as shown previously [8]. These cells were grown to 90% confluency in T75 flasks. The cells were then washed with EDTA, trypsinised, decanted into 15 ml conical tubes, and centrifuged for 4 min at 1,100 rpm at 4 degreesC. The supernatant was removed and the cells resuspended in 4 ml of Dulbecco's modified Eagle medium (DMEM) with 2% serum. After incubation for 2 h at 37 degreesC while shaking at 120 rpm, the cells were centrifuged for 4 min at 1,100 rpm at 4 degreesC and the supernatant removed. Next, the cells were washed twice in Kreb's Ringer phosphate (KRP) buffer, centrifuged for 4 min at 1,100 rpm at 4 degreesC and resuspended in 0.450 ml of KRP buffer with 50 mul of 1.2 mM 14C-labeled urate (Moravek Biochemicals). The cells were then incubated at 37 degreesC with shaking at 120 RPM for 6 min, after which they were placed on ice for 5 min. Finally, the supernatant was removed after centrifugation and the pellet washed twice with cold KRP buffer, before lysis. After incubation in lysis media for 30 min on ice, a final centrifugation step at 1,100 rpm for 1 min was performed, a 500 mul aliquot of the supernatant was added to scintillation fluid (5 ml) and the radioactivity measured using a Beckman LS6500 liquid scintillation counter. The remainder of the supernatant was used for protein quantitation and Western immunoblot. All experiments were done at least three times.
###end p 39
###begin title 40
Western Immunoblot Analysis
###end title 40
###begin p 41
###xml 495 497 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b011">11</xref>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 367 373 <span type="species:ncbi:10090">murine</span>
###xml 435 440 <span type="species:ncbi:10090">mouse</span>
###xml 530 541 <span type="species:ncbi:3704">horseradish</span>
###xml 561 565 <span type="species:ncbi:9925">goat</span>
###xml 571 577 <span type="species:ncbi:9986">rabbit</span>
Cell lysates were solubilised in Laemmli buffer and subjected to SDS-PAGE, transferred onto nitrocellulose membranes, blocked with 5% dry milk in Tris-buffered saline/Tween 20 (TBS-T), and probed with an antibody raised against the human SLC2A9a N terminus (1.5 mug/ml in 1% dry milk/TBS-T), or the human SLC2A9b N terminus (1.0 mug/ml in 1% dry milk/TBS-T). For the murine insulinoma cell (MIN6) lysates, polyclonal antibodies to the mouse SLC2A9a and SLC2A9b, previously described, were used [11]. Blots were then probed with a horseradish peroxidase-coupled goat anti-rabbit secondary antibody (Santa Cruz Biotechnology) and detection was performed using the SuperSignal Dura Western kit (Pierce Biotechnology). Blot quantitation after scanning was carried out using NIH Image.
###end p 41
###begin title 42
###xml 11 16 <span type="species:ncbi:10090">Mouse</span>
Culture of Mouse Insulinoma Cells (MIN6)
###end title 42
###begin p 43
###xml 6 8 6 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b012">12</xref>
###xml 211 212 205 206 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 271 272 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 112 118 <span type="species:ncbi:9913">bovine</span>
MIN6 [12] cells were maintained in DMEM containing 25 mM glucose, supplemented with 15% heat-inactivated foetal bovine serum, 50 muM beta-mercaptoethanol, 100 U/ml penicillin,100 mug/ml streptomycin, 100 mug/ml l-glutamine, 10 mM HEPES, and 1 mM sodium pyruvate, in 5% CO2, 95% air at 37 degreesC. MIN6 cells were used between passages 20 and 30. The radiolabelled urate uptake assays were conducted as described above for the HEK293 cells. For the cold urate competition assays, 50 mul of cold uric acid stock at a concentration of 1 mM dissolved in Tris buffer (pH 8.1) was added to the KRP buffer with labelled urate to give a final concentration of 1 mM unlabeled urate. The remainder of the assay was performed as described above.
###end p 43
###begin title 44
SLC2A9 siRNA Transfection
###end title 44
###begin p 45
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
The polyamine transfection reagent, Trans IT- TKO (Mirus) was used to transfect the insulinoma cells according to the manufacturer's instructions. The mouse SLC2A9 siRNA and scrambled siRNA (negative control) were obtained from Ambion. Cells were transfected for 72 h for protein isolation. Radiolabelled urate uptake assays were conducted as described above.
###end p 45
###begin title 46
###xml 100 112 <span type="species:ncbi:9606">Participants</span>
Association Studies with Serum Urate, Fractional Urate Excretion, Blood Pressure, and Hypertension: Participants
###end title 46
###begin title 47
The Olivetti Heart Study.
###end title 47
###begin p 48
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b012">12</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b013">13</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b014">14</xref>
###xml 355 367 <span type="species:ncbi:9606">participants</span>
The Olivetti Heart Study population is derived from the male work force of the Olivetti factories of Pozzuoli (Naples) and Marcianise (Caserta), Italy. The general characteristics of the study and its methodological procedures have been described [12,13]. The local ethics committee approved the study protocol, and informed consent was obtained from all participants. A total of 1,085 individuals aged 25-74 y were examined in 1994-1995: of these, 907 (83.6%) were seen again in 2002-2004, and of these, 868 individuals had DNA available for genotyping at both time points [14]. We analysed individuals at both time points for association with serum urate and fractional excretion of uric acid and the 1994-1995 dataset only for association with blood pressure and hypertension.
###end p 48
###begin title 49
Whitehall II study.
###end title 49
###begin p 50
###xml 76 81 <span type="species:ncbi:9606">women</span>
###xml 604 616 <span type="species:ncbi:9606">participants</span>
###xml 811 823 <span type="species:ncbi:9606">participants</span>
After ethical clearance the Whitehall study enrolled 10,308 subjects (3,413 women) aged 35-55 y working in the London offices of 20 civil service departments between 1985-1988. In this longitudinal study, blood pressure was recorded at phase 1 (1985-1988), phase 3 (1991-1993), phase 5 (1997-1999), and phase 7 (2003-2004). DNA was stored from phase 7 of the study. For association testing with blood pressure and hypertension we selected individuals from phase 5 as diabetes ascertainment and blood pressure medication records were most complete from this phase. For case-control analyses, hypertensive participants were selected using the following criteria: blood pressure recordings of >/= 145/95 mm Hg, prescribed antihypertensive medication, or a physician diagnosis of hypertension. Normotensive control participants were selected on the basis of blood pressure recordings </= 130/85 mmHg and not taking any antihypertensive medications.
###end p 50
###begin title 51
English Longitudinal Study of Ageing (ELSA).
###end title 51
###begin p 52
###xml 27 39 <span type="species:ncbi:9606">participants</span>
###xml 326 337 <span type="species:ncbi:9606">participant</span>
###xml 427 439 <span type="species:ncbi:9606">participants</span>
After ethical approval the participants were drawn from around 12,000 respondents to the Health Survey for England (HSE) over three separate years (1998, 1999, and 2001) to provide a representative sample of the English population aged 50 y and over. Each individual had a mean of three blood pressure measures taken when the participant was seated, and antihypertensive medications were recorded, DNA was extracted from 5,672 participants in wave 2 (2004). For association testing with blood pressure and hypertension we selected individuals from wave 2. Cases and normotensive controls were defined using the same criteria as the Whitehall II study.
###end p 52
###begin title 53
BRIGHT study.
###end title 53
###begin p 54
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b015">15</xref>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
###xml 577 589 <span type="species:ncbi:9606">participants</span>
The MRC BRIGHT study () comprises 2,500 hypertensive participants and 2,000 normotensive controls of white European ancestry. Case ascertainment and phenotyping has been described previously [15]. Briefly, cases were included if they had blood pressure readings >/= 150/100 mm Hg based on one reading or >/= 145/95 mm Hg based on the mean of three readings. Healthy age- and sex-matched normotensive controls (< 140/90 mm Hg) were recruited using the same strict selection criteria. Ethics Committee approval was received from the multi- and local-research committees, and all participants gave informed written consent.
###end p 54
###begin title 55
London Life Sciences Prospective Cohort Study.
###end title 55
###begin p 56
###xml 111 123 <span type="species:ncbi:9606">participants</span>
The London Life Sciences Prospective Cohort Study (LOLIPOP) is a prospective study of potentially up to 24,000 participants (UK-based individuals of Indian and white European ancestry) recruited primarily for investigating cardiovascular risk factors. For this study we selected white European individuals-485 hypertensive cases and 458 normotensive controls-drawn from the top and bottom 10% of the blood pressure distribution. All blood pressure readings were off-medication.
###end p 56
###begin title 57
The Estonian HYPEST sample collection.
###end title 57
###begin p 58
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 787 788 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 954 955 952 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1091 1092 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1127 1128 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1161 1162 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 13 25 <span type="species:ncbi:9606">participants</span>
###xml 286 291 <span type="species:ncbi:9606">Human</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 613 625 <span type="species:ncbi:9606">participants</span>
The Estonian participants were recruited during 2004-2007 across the entire country in the framework of the HYPEST sample collection (n = 1,823) targeting hypertension risk factors in the Estonian population (permissions no 122/13, 22.12.2003; 137/20, 25.04.2005 by Ethics Committee on Human Research of University of Tartu, Estonia). Hypertensive patients were recruited at the North Estonia Medical Center, Tartu Estonia. Healthy (exclusion criteria: cardiovascular disease, diabetes, and antihypertensive treatment), normotensive individuals were recruited across the whole country. The majority of the HYPEST participants (n = 1,482) possess a documented history of multiple systolic blood pressure (SBP) and diastolic blood pressure (DBP) readings. For this study we defined cases (n = 596) as individuals with either blood pressure readings >/= 160/100 mm Hg based on the median of several measurements or under antihypertensive therapy. Controls (n = 650) were defined as having median blood pressure readings below 140/90 mm Hg. The quantitative association analysis of SBP and DBP (n = 1,284) included both untreated (n = 881) and treated individuals (n = 403).
###end p 58
###begin title 59
Genotyping
###end title 59
###begin p 60
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b016">16</xref>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b017">17</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b018">18</xref>
###xml 344 356 <span type="species:ncbi:9606">participants</span>
Two variants of SLC2A9 (SNPs rs7442295 and rs13113918) were investigated in the Olivetti Study for association with serum urate and fractional urinary urate excretion. For association analyses with blood pressure and hypertension, one intragenic SNP (rs13113918) was genotyped in each cohort. SNP genotyping in Olivetti, Whitehall II, and ELSA participants was performed with TaqMan assay (Applied Biosystems) followed by allelic discrimination using the ABI PRISM 7900HT Sequence Detection System and software (SDSv2.0, Applied Biosystems) [16]. SNP genotyping in BRIGHT, HYPEST, and LOLIPOP subjects was performed using the KASPar chemistry, a competitive allele-specific PCR SNP genotyping system using FRET quencher cassette oligonucleotides [17]. SNPs were checked for departure from Hardy-Weinberg equilibrium, low minor allele frequency (<1%), and high level of missing data. Allele frequencies at both sites were similar to those previously reported in Hapmap [18].
###end p 60
###begin title 61
Statistical Analysis
###end title 61
###begin p 62
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
For the Olivetti study, between-group comparisons were performed using unpaired t-tests for serum urate and fractional uric acid excretion. Analysis of covariance was used to model age and body mass index (BMI) covariation.
###end p 62
###begin p 63
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b019">19</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b020">20</xref>
In order to test for associations with SNP rs13113918 we performed linear regression for the quantitative phenotypes (SBP and DBP) in Olivetti, Whitehall II, ELSA, and HYPEST reported as effect size in mm Hg with 95% confidence intervals. We used logistic regression for the qualitative phenotype hypertension (HYP) in all the studies reported as an odds ratio with 95% confidence intervals. Age, gender, and BMI were included as covariates in all models. We tested additive models of inheritance using either PLINK software [19] or SAS v9.1. For individuals on antihypertensive medication, we adjusted systolic and diastolic blood pressure measures by adding 15 mm Hg to systolic and 10 mm Hg to diastolic readings [20]. Individuals with BMI > 35 and those with diabetes were excluded from all analyses.
###end p 63
###begin p 64
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b021">21</xref>
Inverse-variance weighted meta-analysis was performed using the "metan" [21] procedure in Stata 10.0.
###end p 64
###begin title 65
Results
###end title 65
###begin title 66
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human SLC2A9 Is a High-Capacity Urate Transporter
###end title 66
###begin p 67
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 151 160 151 160 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">X. laevis</named-content>
###xml 221 222 221 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 352 361 352 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050197-sg001">Figure S1</xref>
###xml 719 727 719 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 1184 1192 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 1329 1330 1328 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1330 1331 1329 1330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 1349 1350 1347 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 1350 1353 1348 1351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 1610 1618 1607 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 151 160 <span type="species:ncbi:8355">X. laevis</span>
###xml 564 569 <span type="species:ncbi:9606">human</span>
###xml 963 968 <span type="species:ncbi:9606">human</span>
###xml 1025 1030 <span type="species:ncbi:9606">human</span>
###xml 1522 1527 <span type="species:ncbi:9606">human</span>
To test whether SLC2A9 splice variants act as urate transporters we separately microinjected synthetic human SLC2A9a and SLC2A9b mRNA transcripts into X. laevis oocytes and measured uptake or efflux of radiolabelled urate. Both proteins were readily expressed in the oocyte plasma membrane within a couple of days as confirmed by immunohistochemistry (Figure S1). However, we studied the oocytes 4 d after mRNA injection so that urate fluxes could be determined under the same conditions as previously published for SLC2A9 mediated hexose transport. We found that human SLC2A9a and SLC2A9b mediated very rapid urate fluxes which necessitated incubation for only 20 min in subsequent kinetic and inhibition experiments (Figure 1A). In contrast, uptake of urate into non-injected eggs was very slow, indicating negligible endogenous transport activity for this substrate. Transport was then measured over a range of urate concentrations, which bracketed the normal human physiological plasma concentrations (200-500 muM). Both human SLC2A9a- and SLC2A9b-mediated urate fluxes showed saturation and were identical, so data for the two splice variants were combined for kinetic analysis. Figure 1B shows the averaged data from six such experiments and nonlinear regression analysis was used to fit a Michaelis-Menten function with a Km of 981 muM and a Vmax of 304 pmol/oocyte/20 min. The insert shows the Eadie-Hofstee plot for the same data. In contrast, we were unable to detect any urate flux (100 muM) mediated by either human GLUT1 (SLC2A1) or GLUT2 (SLC2A2), both class I facilitative glucose transporters (Figure 1C).
###end p 67
###begin title 68
###xml 84 98 84 98 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Xenopus laevis</named-content>
###xml 58 63 <span type="species:ncbi:9606">Human</span>
###xml 84 98 <span type="species:ncbi:8355">Xenopus laevis</span>
Characterisation of Urate Fluxes and Kinetics Mediated by Human SLC2A9 Expressed in Xenopus laevis Oocytes and the Effect of Short-Chain Fatty Acids and Uricosurics on Urate Transport
###end title 68
###begin p 69
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 402 409 395 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
(A) Time course of SLC2A9a-mediated urate uptake into Xenopus oocytes. Oocytes were injected with SLC2A9a cRNA or water and 4 d later incubated with 10 muM urate at 22 degreesC for the time periods indicated. Symbols represent the average uptake into ten oocytes per time point, with error bars representing the standard error of the mean (SEM). Solid circles show total uptake into oocytes expressing SLC2A9a cRNA, open circles urate uptake into water-injected oocytes, and inverted triangles the net uptake obtained by subtracting the water data from the total uptake for each time point.
###end p 69
###begin p 70
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 237 244 237 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 385 386 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 405 406 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 406 409 405 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 16 21 <span type="species:ncbi:9606">human</span>
(B) Kinetics of human SLC2A9-mediated urate uptake in Xenopus oocytes. Symbols represent the mean data from six separate experiments each using ten oocytes per substrate concentration. Uptake was measured in oocytes injected with either SLC2A9a or SLC2A9b cRNA 4 d prior and corrected for uptake into water-injected oocytes. The curve was fitted by nonlinear regression analysis. The Km = 981 muM and the Vmax = 304 pmol/oocyte/20 min. Insert shows an Eadie-Hofstee plot of the same data.
###end p 70
###begin p 71
###xml 94 101 94 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 352 359 351 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 510 516 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 812 818 810 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A1</italic>
###xml 830 836 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A2</italic>
###xml 1028 1029 1025 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
(C) Effect of uricosemics and short chain fatty acids on human SLC2A9a mediated urate uptake. Xenopus oocytes were injected with water or SLC2A9a cRNA and urate uptake measured 4 d later. Oocytes were incubated with 10 muM urate for 20 min, and bars represent net uptake determined by subtracting uptake into water-injected eggs from total uptake into SLC2A9a expressing oocytes, error bars are the SEM. Note: at no time was the urate uptake into the water-injected eggs more than 11% of the total uptake into SLC2A9-expressing oocytes. Compounds used were: no additional reagent (Cont), lactate 1 mM (Lac), pyruvate 1 mM (Pyr), butyrate 1 mM (But), acetate 1 mM (Ace), probenecid 1 mM (Prob), furosemide 100 muM (Furo), and phloretin 1 mM (Phlo). For comparison, a separate series of oocytes were injected with SLC2A1 (GLUT1) or SLC2A2 (GLUT2) cRNA and 100 muM urate uptake measured 4 d later using 30 min incubation times. Bars represent net uptake corrected for uptake into water-injected oocytes. *Significant inhibition at p </= 0.05.
###end p 71
###begin p 72
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
(D) Dose-dependent effect of benzbromarone on SLC2A9a-mediated urate uptake. Oocytes were injected with SLC2A9a cRNA or water and 4 d later were incubated with 10 muM urate for 20 min in the presence of 0, 1, 10, or 100 muM benzbromarone. Points represent the mean net uptake into ten oocytes corrected for uptake into water-injected eggs. Error bars were smaller than the data points.
###end p 72
###begin title 73
Transport of Urate by SLC2A9 Shows Limited Sensitivity to Uricosurics
###end title 73
###begin p 74
###xml 311 319 309 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 439 440 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 440 441 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 612 613 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 622 630 618 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 861 862 856 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 871 879 866 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
###xml 1048 1049 1043 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1058 1066 1053 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g001">Figure 1</xref>
A number of compounds known to promote urate loss in the urine via inhibition of other renal urate transporters such as URAT1 were tested to determine if they reduced SLC2A9 mediated urate transport. Benzbromarone showed a dose-responsive inhibition with 10 muM reducing urate uptake by 34% and 100 muM by 80% (Figure 1D). Additional kinetic analyses using two concentrations of urate (10 and 100 muM) and a Dixon analysis showed that the Ki for benzbromarone inhibition of urate transport mediated by SLC2A9a was 27 muM. However, probenecid at a concentration of 1 mM had no significant effect on urate uptake, p > 0.05 (Figure 1C). Similarly, furosemide had no significant effect at 100 muM, and, of the short chain fatty acids lactate, pyruvate, butyrate, and acetate at a concentration of 1 mM, only lactate induced a small and just significant inhibition, p < 0.05 (Figure 1C). Finally, the class I hexose transporter inhibitor phloretin had no significant effect on urate transport (< 10% inhibition) when applied at a concentration of 1 mM, p > 0.05 (Figure 1C).
###end p 74
###begin title 75
SLC2A9 Mediates Exchange of Urate for Glucose or Fructose
###end title 75
###begin p 76
###xml 348 356 347 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g002">Figure 2</xref>
###xml 437 438 435 436 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 450 451 448 449 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 462 470 460 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g002">Figure 2</xref>
###xml 476 477 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g002">2</xref>
###xml 1609 1610 1605 1606 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 1620 1621 1616 1617 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 1632 1633 1628 1629 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1785 1786 1781 1782 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 1909 1918 1905 1914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g003">Figures 3</xref>
###xml 1924 1925 1920 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g003">3</xref>
###xml 2044 2045 2040 2041 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 2293 2298 2289 2294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 2393 2394 2389 2390 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 2556 2564 2552 2560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g003">Figure 3</xref>
Because SLC2A9a and SLC2A9b have previously been characterized as high-affinity, low-capacity glucose and fructose transporters, we tested the ability of these two hexoses to inhibit urate fluxes and, conversely, for urate to inhibit hexose uptake. Surprisingly, concentrations of glucose up to 1 mM had no effect on the transport of 10 muM urate (Figure 2B), and urate concentrations of up to 2 mM had no effect on the uptake of 50 muM d-glucose or d-fructose (Figure 2A and 2C). Note that the rates of urate transport were significantly greater than those for glucose. Urate fluxes were measured at 5 or 10 muM for only 20 min, whereas glucose rates were determined using 50 muM substrate for 30 min. Thus, converting flux rates to the same time period and equivalent concentrations suggest that urate is transported by SLC2A9 at rates 45- to 60-fold faster. The lack of significant competition between the hexoses and urate suggests that urate binds to a site on SLC2A9 that is different from the binding site for the hexoses. However, it could be argued that the injection of SLC2A9 mRNA was inducing expression of an endogenous protein that could separately mediate urate uptake. Therefore, we attempted to determine whether SLC2A9 could exchange hexoses with urate, providing further support for a single pathway mechanism. Since glucose and fructose are both rapidly phosphorylated upon entry into the oocyte, only urate efflux could be used to give a meaningful estimate of exchange rates. Oocytes were injected with radiolabelled urate and the efflux determined in the presence of 5 mM extracellular d-glucose, d-fructose, l-glucose, or 2 mM urate. Urate efflux could be described by a single exponential curve over a period of up to 20 min, and the presence of extracellular d-glucose greatly accelerated urate movement, while fructose did so to a lesser degree (7-fold versus 3-fold, respectively, Figures 3A and 3B). Extracellular cold urate accelerated the efflux of radiolabelled urate to the greatest degree, while extracellular l-glucose had no effect. Thin-layer chromatography was used to analyze the efflux medium, and only urate and no allantoin were detected on the plate for both water-injected eggs and those expressing SCL2A9a. Thus, SLC2A9 exhibits classical exchange trans-stimulation between urate and glucose or fructose. The rate of loss of injected radiolabelled l-glucose into the efflux medium was negligible, indicating that the injection protocol did not result in a nonspecific leakage of the substrate from the oocytes (Figure 3A).
###end p 76
###begin title 77
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 32 37 <span type="species:ncbi:9606">Human</span>
Interaction between Hexoses and Human SLC2A9a-Mediated Urate Uptake in Xenopus Oocytes
###end title 77
###begin p 78
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 238 245 238 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
Oocytes were injected with SLC2A9a cRNA 4 d prior to uptake experiments. Symbols represent mean net substrate uptake and error bars the SEM for measurements made in 6-10 oocytes per condition. Total uptake of substrates was measured into SLC2A9a cRNA-injected oocytes and then corrected for the uptake measured under identical conditions using water injected oocytes from the same batch of eggs.
###end p 78
###begin p 79
(A) Uptake over 30 min of 50 muM glucose in the presence of increasing concentrations of urate.
###end p 79
###begin p 80
(B) Uptake over 20 min of 5 muM urate in the presence of increasing concentrations of glucose.
###end p 80
###begin p 81
(C) Uptake over 30 min of 50 muM fructose in the presence of increasing concentrations of urate.
###end p 81
###begin p 82
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 154 155 154 155 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 260 262 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 279 280 272 273 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 354 361 347 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 4 9 <span type="species:ncbi:9606">Human</span>
(D) Human SLC2A9a-mediated glucose and urate exchange. Oocytes injected with SLC2A9a cRNA or water, 4 d prior, were incubated with non-radiolabelled 2 mM l-glucose or 2 mM urate for 1 h. Oocytes were then washed and then incubated at 22 degreesC for 30 min in 14C-labeled 10 muM d-glucose. Bars represent the average total uptake into 20 eggs expressing SLC2A9a or water-injected eggs, and the difference between the two, the net uptake. Error bars represent the SEM.
###end p 82
###begin title 83
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human SLC2A9a-Mediated Urate Efflux from Xenopus Oocytes
###end title 83
###begin p 84
###xml 28 29 28 29 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 198 200 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 267 268 267 268 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 495 496 488 489 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 526 527 519 520 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 662 663 655 656 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
(A) Comparison of urate and l-glucose efflux from SLC2A9a-expressing oocytes. Oocytes injected with SLC2A9a cRNA 4 d prior (triangles) or water-injected eggs (circles or squares) were injected with 14C-labelled urate (circles, triangles, or diamonds) or 14C-labelled l-glucose (filled squares) to give an estimated initial intracellular concentration of 200 muM. 20 oocytes per condition were incubated at 22 degreesC in efflux medium, which was sampled every 2 min. Efflux media contained 5 mM d-glucose (open circles), 5 mM l-glucose (filled squares, circles or triangles), or 2 mM urate (filled diamonds). Data points represent the log percentage of urate or l-glucose remaining in the oocytes for each time point. Lines were fitted by linear regression.
###end p 84
###begin p 85
###xml 67 68 67 68 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 80 81 80 81 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 403 404 396 397 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 436 437 429 430 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 473 474 466 467 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
(B) Acceleration of SLC2A9a mediated urate efflux by extracellular d-glucose or d-fructose. Oocytes injected with SLC2A9a cRNA 4 d prior (triangles) or water-injected eggs were injected with 14C-labelled urate to give an estimated intracellular concentration of 200 muM. 20 oocytes per condition were incubated at 22 degreesC in efflux medium, which was sampled every 2 min. Efflux media contained 5 mM d-glucose (filled circles), 5 mM l-glucose (filled triangles) or 5 mM d-fructose (open circles). Data points represent the log percentage of urate remaining in the oocytes for each time point corrected for the efflux of urate from the water-injected eggs under the same conditions. Lines were fitted by linear regression.
###end p 85
###begin p 86
###xml 191 192 190 191 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 216 217 215 216 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 333 334 332 333 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 344 352 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g002">Figure 2</xref>
The exchange of urate for glucose was confirmed by preloading the oocytes with 2 mM cold urate for 1 h and then, after washing, to remove extracellular urate, measuring the uptake of 100 muM d-glucose. The influx of d-glucose was increased 3-fold by intracellular urate in SLC2A9a-expressing eggs compared to preincubation with 2 mM l-glucose (Figure 2D). These data confirm that SLC2A9a can exchange extracellular glucose for intracellular urate.
###end p 86
###begin title 87
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Increased Urate Uptake by Kidney Cells Overexpressing SLC2A9 Isoforms
###end title 87
###begin p 88
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b021">21</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 815 823 815 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g004">Figure 4</xref>
###xml 846 854 846 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g004">Figure 4</xref>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b008">8</xref>
###xml 307 312 <span type="species:ncbi:9606">human</span>
Both overexpressed proteins appear as a smear of glycosylated bands between 37 and 50 kDa, as previously reported using a different polyclonal antibody to the C terminus that was unable to distinguish SLC2A9a from SLC2A9b [8,21]. Previous studies had also already demonstrated plasma membrane expression of human (h) SLC2A9 in these cell lines [8]. In order to check the specificity of each antibody, total protein from cells overexpressing the different splice variants were loaded side by side in polyacrylamide gels and immunoblotted with the two antibodies separately. Each individual antibody detected the correct overexpressed protein but not the alternative splice variants. Both SLC2A9a and SLC2A9b were expressed at low levels endogenously in HEK293 cells as seen by the multiple bands in lanes 1 and 3 of Figure 4A and lanes 1 and 2 of Figure 4B. In prior studies we have demonstrated that these multiple bands in HEK cells reduce to one band at 37 kDa upon deglycosylation [8]. In the presence of preimmune sera (unpublished data) no specific bands were detected.
###end p 88
###begin title 89
###xml 15 20 <span type="species:ncbi:9606">Human</span>
###xml 93 98 <span type="species:ncbi:9606">Human</span>
Specificity of Human SLC2A9a and SLC2A9b Antibodies and Urate Uptake into SLC2A9 Transfected Human Embryonic Kidney Cells
###end title 89
###begin p 90
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hSLC2A9a</italic>
###xml 190 197 190 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 229 236 229 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
(A) Western blotting of hSLC2A9 expressed in HEK cells. Expression of hSLC2A9a was detected as a broad band at approximately 50 kDa by a polyclonal antibody raised against the N terminus of SLC2A9a in HEK293 cells overexpressing SLC2A9a (middle lane, Slc2a9a) but not detected in cells overexpressing SLC2A9b (right lane, Slc2a9b), or nontransfected HEK cells (left lane, HEK).
###end p 90
###begin p 91
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hSLC2A9b</italic>
###xml 136 144 136 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hSLC2A9b</italic>
###xml 176 184 176 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hSLC2A9b</italic>
###xml 249 257 249 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hSLC2A9a</italic>
(B) Expression of hSLC2A9b in transfected HEK293 cells. hSLC2A9b was detected by a polyclonal antibody raised against the N terminus of hSLC2A9b in HEK293 cells overexpressing hSLC2A9b (right lane, Slc2a9b), but not detected in cells overexpressing hSLC2A9a (middle lane, Slc2a9a).
###end p 91
###begin p 92
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 206 213 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
###xml 338 339 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 350 351 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 132 137 <span type="species:ncbi:9606">human</span>
(C) Increase in urate uptake in HEK293 cells overexpressing either hSLC2A9a or hSLC2A9b. Radiolabelled urate uptake was measured in human embryonic kidney cells, which were stably overexpressing SLC2A9a or SLC2A9b as compared to their respective nontransfected controls. Uptakes of 120 muM urate were measured over 6 min at 37 degreesC. *p < 0.05; **p < 0.02.
###end p 92
###begin p 93
###xml 238 246 238 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g004">Figure 4</xref>
###xml 108 113 <span type="species:ncbi:9606">human</span>
We observed that radiolabelled uric acid was transported into the HEK293 cells stably overexpressing either human SLC2A9a or SLC2A9b at the cell surface. The rate of urate uptake was at least 2-fold greater than for control HEK293 cells (Figure 4C).
###end p 93
###begin title 94
Confirmation of SLC2A9-Mediated Urate Transport in a Second Mammalian Cell Line
###end title 94
###begin p 95
###xml 340 348 340 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g005">Figure 5</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b011">11</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b011">11</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b022">22</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b022">22</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b024">24</xref>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b011">11</xref>
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
###xml 149 155 <span type="species:ncbi:10090">murine</span>
###xml 220 225 <span type="species:ncbi:10090">mouse</span>
###xml 324 330 <span type="species:ncbi:10090">murine</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 443 448 <span type="species:ncbi:10090">mouse</span>
###xml 529 534 <span type="species:ncbi:10090">Mouse</span>
###xml 676 681 <span type="species:ncbi:10090">mouse</span>
###xml 799 804 <span type="species:ncbi:10090">mouse</span>
In order to verify the findings in kidney cells, we used a mouse insulinoma cell line (MIN6 cells) endogenously expressing detectable levels of both murine SLC2A9a and SLC2A9b protein. We verified the expression of both mouse SLC2A9a and SLC2A9b protein by using antibodies specifically raised against the N termini of each murine isoform (Figure 5A). We have previously reported SLC2A9 expression in MIN6 cells and islets from both human and mouse [11]. The specificity of these antibodies has been previously reported [11,22]. Mouse SLC2A9a and SLC2A9b in MIN6 cells appear as a doublet with the isoform-specific antibodies as previously shown in both cell lines as well as mouse and ovine tissues [22-24]. The molecular weights are consistent with that published previously for these isoforms in mouse tissue [11].
###end p 95
###begin title 96
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 43 48 <span type="species:ncbi:10090">Mouse</span>
Expression of SLC2A9 and Urate Uptake into Mouse Insulinoma MIN6 Cells
###end title 96
###begin p 97
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 115 121 <span type="species:ncbi:10090">murine</span>
(A) Western blotting of mouse SLC2A9 in MIN6 cells. Cell lysates were analyzed by Western blot using antibodies to murine SLC2A9a and SLC2A9b of MIN6 cell lysates.
###end p 97
###begin p 98
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSLC2A9a</italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
###xml 205 207 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 326 327 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 122 127 <span type="species:ncbi:10090">mouse</span>
(B) 14C-urate uptake into MIN6 cells is competitively inhibited by cold urate. Radiolabelled urate uptake was measured in mouse insulinoma cells, which endogenously express mSLC2A9a or mSLC2A9b. Uptake of 14C-urate, 120 muM, was measured for 6 min at 37 degreesC in the presence or absence of an additional 1mM cold urate. ** p < 0.02.
###end p 98
###begin p 99
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9a</italic>
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9b</italic>
###xml 97 104 97 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSLC2A9</italic>
###xml 162 170 162 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSLC2A9-</italic>
###xml 272 280 272 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSLC2A9a</italic>
###xml 294 302 294 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mSLC2A9b</italic>
(C) SLC2A9a and SLC2A9b expression is reduced by treatment of MIN6 cells with siRNA specific for mSLC2A9. Cells were treated with either scrambled RNA (scRNA) or mSLC2A9-specific siRNA and cell lysates run on a Western blot and probed with an antibody specific for either mSLC2A9a (mGLUT9a) or mSLC2A9b (mGLUT9b).
###end p 99
###begin p 100
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 289 290 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(D) Reduction of urate uptake into MIN6 cells by transfection with siRNA targeted to SLC2A9. MIN6 cells were transfected with either SLC2A9-specific siRNA9 or scrambled RNA (scRNA). 14C-urate, 120 muM, uptake into transfected or untransfected cells was measured for 6 min at 37 degreesC. *p < 0.05.
###end p 100
###begin p 101
###xml 79 87 79 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g005">Figure 5</xref>
###xml 328 336 328 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g005">Figure 5</xref>
MIN6 cells take up radiolabelled urate at a rate of 6-7 pmoles/min/mg protein (Figure 5B). In order to test the specificity of SLC2A9a and SLC2A9b for urate, non-radiolabelled urate was added to the uptake assay at a final concentration of 1 mM. The cold urate significantly inhibited radiolabelled uptake by approximately 50% (Figure 5B). These findings suggest that the SLC2A9 isoforms are specific for urate.
###end p 101
###begin title 102
Urate Uptake Is Inhibited by siRNA against SLC2A9 but Not Scrambled RNA
###end title 102
###begin p 103
###xml 314 322 314 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g005">Figure 5</xref>
###xml 395 403 395 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050197-g005">Figure 5</xref>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
As a final check of the specificity of the SLC2A9 transporter for urate, endogenous expression of mouse SLC2A9a and SLC2A9b in MIN6 cells was knocked down by small interfering RNAs (siRNAs) for both isoforms. Western immunoblotting confirmed a significant decrease in SLC2A9a and SLC2A9b expression in MIN6 cells (Figure 5C). As a result, radiolabelled urate uptake was significantly decreased (Figure 5D) by approximately 50%. Expression and uptake were unaffected by the scrambled RNA.
###end p 103
###begin title 104
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Association of SLC2A9 Gene Variants with Serum and Fractional Excretion of Urate
###end title 104
###begin p 105
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b012">12</xref>
###xml 655 662 655 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t001">Table 1</xref>
The Olivetti Heart Study has previously shown strong correlations between uric acid, urate tubular handling, and blood pressure level [12]. We genotyped rs7442295, which had demonstrated the strongest support for association with urate in our previous study, and rs13113918, an intragenic SNP in 868 individuals that had been surveyed at two time points (1994-1995 and 2002-2004). After adjusting for age we confirmed association of both variants with serum uric acid level and detected a complementary association of these variants with reduced urate fractional excretion, which fits with common allelic variation reducing urate clearance by the kidney (Table 1). These associations were evident at both 1994-1995 and 2002-2004 time- points, and after adjustment for BMI and after exclusion of subjects on antihypertensive therapy (unpublished data).
###end p 105
###begin p 106
Genetic Association Results for SNPs rs13113918 and rs7442295 in the Olivetti Heart Study in 1994-1995 and 2002-2004 with Serum Uric Acid and Fractional Excretion of Urinary Urate
###end p 106
###begin title 107
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Association Studies of the SLC2A9 Gene with Blood Pressure
###end title 107
###begin p 108
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b007">7</xref>
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t002">Table 2</xref>
###xml 369 376 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t003">Table 3</xref>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 593 599 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 649 650 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 775 776 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 853 860 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t003">Table 3</xref>
For reporting our results here we focus upon the additive model for all cohort analyses, because the association of SLC2A9 SNPs with serum urate is best described by this model [7]. We performed a quantitative genetic analysis of blood pressure variation with an intragenic SNP rs13113918 in four populations; demographic details for each are summarised in Table 2. In Table 3 we show the analysis of each of these cohorts and the global p-value from meta-analysis of systolic and diastolic blood pressure. We found no association with SBP (meta-analysis for SBP showed the effect size of the SLC2A9 variant to be -0.12 mm Hg, 95% CI -0.68 to 0.44, p = 0.66) or DBP (meta-analysis for DBP showed the effect size of the SLC2A9 variant to be -0.04 mm Hg, 95% CI -0.39 to 0.31, p = 0.82) within each population or in meta-analyses under an additive model (Table 3).
###end p 108
###begin p 109
Demographic Characteristics Per Cohort for Genetic Studies
###end p 109
###begin p 110
Association of SNPs rs13113918 with SBP and DBP under an Additive Genetic Model of Inheritance
###end p 110
###begin title 111
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
Association Studies of the SLC2A9 Gene with Hypertension
###end title 111
###begin p 112
###xml 522 529 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t002">Table 2</xref>
###xml 604 611 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050197-t004">Table 4</xref>
###xml 681 687 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
We analysed rs13113918 under additive model of inheritance within cases and controls from the BRIGHT study (2,052 hypertensives and 1,637 normotensive controls), the Estonian HYPEST study (596 hypertensives and 650 normotensive controls), the LOLIPOP study (498 hypertensives and 498 normotensive controls), Olivetti 94 (182 hypertensives and 549 normotensive controls), Whitehall II (961 hypertensives and 2,365 normotensive controls) and ELSA (960 hypertensives and 949 normotensive controls) with demographics shown in Table 2. The results of our meta-analysis combining six case-control studies (see Table 4) did not show a significant association between hypertension and the SLC2A9 variant tested (odds ratio 0.98, 95% CI 0.91 to 1.05, p > 0.6).
###end p 112
###begin p 113
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 80 92 <span type="species:ncbi:9606">Participants</span>
Results of SNP rs13113918 of SLC2A9 within Individual Hypertensive Case-Control Participants from All Resources and in Meta-analysis Analysed under an Additive Model Testing for Influence on Hypertension
###end p 113
###begin title 114
Discussion
###end title 114
###begin p 115
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b006">6</xref>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b007">7</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b025">25</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b026">26</xref>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 569 570 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 570 573 558 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 879 880 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b007">7</xref>
###xml 1186 1188 1171 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b025">25</xref>
###xml 1189 1191 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b027">27</xref>
###xml 194 199 <span type="species:ncbi:9606">human</span>
Recent genome-wide association scans identified and replicated association between SNPs at the SLC2A9 gene locus and serum urate and with gout [6,7,25,26]. In this study we have shown that both human SLC2A9 splice variants, SLC2A9a and SLC2A9b, can mediate urate fluxes at a very high rate and significantly faster than their facilitated transport of either glucose or fructose. The kinetics indicate that the transporter's apparent capacity for substrate, or Km value (approximately 1 mM), is above the basal, physiologic plasma concentrations of urate. Moreover, the Vmax value indicates a high-capacity transporter. All of these data suggest that this membrane protein plays an important role in the handling of urate in the proximal nephron, which completely fits with the findings from genome-wide scans of common allelic variation elevating urate by 20 mumol/l per allele [7]. In the context of everyday clinical practice this genetic influence on urate is equivalent to 5%-10% of the normal range of serum urate (180 mumol/l to 420 mumol/l), which is not trivial. These findings are confirmed by complementary functional studies on SLC2A9 in relation to urate handling and gout [25-27].
###end p 115
###begin p 116
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b028">28</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b029">29</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b030">30</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b031">31</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b032">32</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b033">33</xref>
Current models of urate handling in the proximal convoluted tubule indicate that several types of transporter are involved in the fluxes of urate across both the apical and the basolateral membranes of the epithelial cells. In the apical membrane, these transporters include URAT1, a urate/lactate exchanger that mediates urate movement from urine to epithelium [28]; OATv1, a putative voltage dependent organic anion transporter [29]; MRP4, an ATP driven pump [30]; and UAT, a postulated urate channel [31]. At the other pole of the cells two of the organic anion exchangers, OAT1 and OAT2, present in basolateral membrane, are thought to be able to handle urate, but their physiological role remains to be confirmed [32,33]. Therefore at present there is a well-defined absorptive route across the apical membrane via UAT1 and a secretory route via MRP4, while the means by which urate can either leave the renal epithelium and enter the blood or move in the opposite direction across the basolateral membrane remains to be confirmed.
###end p 116
###begin p 117
###xml 163 169 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 209 212 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">max</sub>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b011">11</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b034">34</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b035">35</xref>
###xml 301 306 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
Recently, it has been proposed that both SLC2A9 proteins are high-affinity glucose/fructose transporters. However, when compared with the principal members of the SLC2A9 gene family their transport capacity (Vmax) is very low [11,34]. We now have evidence that urate is a preferred substrate for both human SLC2A9 variants and for the mouse orthologue. The ability of SLC2A9 to exchange urate with glucose in the absence of competition between these two substrates when present on the same side of the membrane indicates that the protein has separate binding sites. This is not a unique phenomenon in exchange proteins, as the glycerol-6-phosphate transporter exchanges glycerol-6-phosphate for inorganic phosphate [35].
###end p 117
###begin p 118
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b036">36</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b040">40</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b041">41</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b043">43</xref>
This ability of SLC2A9 to exchange glucose and, to a lesser degree, fructose for urate may be physiologically important. The renal proximal nephron plays a major role in the reabsorption of glucose from the urine using a combination of sodium-coupled hexose transporters, SGLT1 and SGLT2, and members of the SLC2A family, GLUTs 2, 5, and possibly 9 [36-40]. Furthermore, the proximal convoluted tubular epithelium is a major site of gluconeogenesis, converting pyruvate to glucose, which is then released across the basolateral membrane into the blood [41-43]. Our data showing that SLC2A9a can exchange glucose for urate suggest that this protein might play an important role in the secretion of urate from the blood into the urine. Glucose in the urine could exchange for urate in the proximal convoluted tubule epithelial cells across the apical membrane, resulting in the release of urate back into the urine. In addition, glucose in the epithelial cells resulting both from reabsorption and neogenesis could exchange for plasma urate across the basolateral membrane, promoting the accumulation of urate in the cells. Furthermore, such a mechanism could explain the known correlation between the glycosuria seen in diabetes and the reduction in plasma urate levels. The increased glucose in the urine could accelerate the SLC2A9-mediated urate efflux across the apical membrane of the proximal convoluted tubule, but further work is needed to confirm this hypothesis.
###end p 118
###begin p 119
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b044">44</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b046">46</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b047">47</xref>
Therefore, our findings, in combination with epidemiologic data showing correlation of elevated serum urate with diabetes, metabolic syndrome, obesity, and hyperinsulinaemia, provide a potential mechanism for these associations that warrants further investigation [44-46]. In this context it is of particular interest that recent data from the Health and Nutrition Survey shows correlation between consumption of sugar-based soft drinks with serum urate levels and gout, which might be partly explained by sugar-facilitated uptake of urate by SLC2A9 isoforms [47].
###end p 119
###begin p 120
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b005">5</xref>
###xml 648 649 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b002">2</xref>
###xml 674 675 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 675 676 674 675 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
Probenecid and benzbromarone are uricosuric drugs that inhibit renal uptake of urate via URAT 1 on the apical proximal nephron membrane [5]. We found that probenecid had no effect on urate uptake into SLC2A9a-expressing oocytes, whereas benzbromarone showed a dose-dependent inhibition. The significant inhibition of urate transport by 10 and 100 muM benzbromarone implies that there are common features in the binding sites for urate in both URAT1 and SLC2A9a. When in clinical use benzbromarone promoted the loss of urate in the urine; this is believed to be a consequence of an inhibition of uptake across the apical membrane mediated by URAT1 [2]. In contrast, the high Ki of 27 muM for benzbromarone action on SLC2A9 suggests that at therapeutic doses this drug would have a minimal effect on urate transport mediated by this protein and so does not affect urate secretion.
###end p 120
###begin p 121
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b048">48</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b012">12</xref>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 693 699 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b025">25</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050197-b027">27</xref>
The Olivetti Heart Study has previously found a strong longitudinal relationship of serum urate levels with blood pressure [48]. The authors also reported a correlation of urate with reduced fractional clearance of lithium as an index of sodium reabsorption in the proximal nephron. This finding could reflect sodium retention and offer a mechanism for previously reported associations of urate and blood pressure [12]. The two SNPs genotyped in the Olivetti cohort validate association of the SLC2A9 locus with serum urate and demonstrate the association of both SNPs with reduced urinary urate excretion at two time points 8 y apart. This provides additional support for our hypothesis that SLC2A9 variants reduce urinary urate loss and is further confirmed by recent cross-sectional findings for this gene in gout [25-27].
###end p 121
###begin p 122
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
In view of the additive influence of alleles of SLC2A9 on serum uric acid and urinary urate excretion, we explored a relationship between SLC2A9 SNPs with systolic and diastolic blood pressure in 11,629 individuals under an additive model. This analysis showed no significant association between SNP rs13113918 and blood pressure. Furthermore, we did not find any evaluated association of the same SLC2A9 SNP with hypertension under an additive model in 5,249 hypertensive cases and 6,648 normotensive controls drawn from all the studies. In the context of this large-scale case-control and population-based cohorts we conclude that there is no support for an association with blood pressure using the most biologically plausible genetic model.
###end p 122
###begin title 123
Limitations of This Study
###end title 123
###begin p 124
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
We have not defined precisely the causative variant of SLC2A9 responsible for elevated serum urate and reduced urinary urate clearance. There are several known SNPs within the gene region that might influence function of the SLC2A9 protein. Such studies will be facilitated by detailed re-sequencing of the SLC2A9 gene to establish a comprehensive inventory of genetic variation across this locus. In addition to dietary and metabolic influences on uric acid levels there will be other, as-yet unidentified genetic influences on serum urate level that may contribute to epidemiologic correlations with metabolic syndrome, diabetes, gout, and cardiovascular disease.
###end p 124
###begin title 125
Conclusion
###end title 125
###begin p 126
###xml 64 70 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
In this paper we have translated the genetic association of the SLC2A9 locus with serum urate derived from genome-wide scanning into a functional confirmation that SLC2A9 splice variants acts as a high-capacity urate transporter that can be facilitated by exchange with hexoses and inhibited by high concentrations of some uricosurics and siRNA technology. These findings offer novel potential pathogenic mechanisms and new drug targets for diseases such as gout.
###end p 126
###begin title 127
Supporting Information
###end title 127
###begin title 128
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus</italic>
Expression of SLC2A9a or 9b in Xenopus Oocyte Plasma Membrane after cRNA Injection
###end title 128
###begin p 129
###xml 335 336 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 338 339 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 345 346 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">z</italic>
Oocytes were injected with 50 nl (1 ng/nl) SLC2A9a or SLC2A9b cRNA or water and incubated at 18 degreesC for 4 d. The expression of SLC2A9a and SLC2A9b was visualized using a primary antibody to the same C-terminal peptide sequence of both proteins, a fluorescent secondary antibody, and confocal microscopy. All three images show the x, y, and z within the same focal plane.
###end p 129
###begin p 130
(A) Water-injected oocyte.
###end p 130
###begin p 131
(B) SLC2A9a.
###end p 131
###begin p 132
(C) SLC2A9b.
###end p 132
###begin p 133
(204 KB PDF)
###end p 133
###begin p 134
Click here for additional data file.
###end p 134
###begin p 135
###xml 13 25 <span type="species:ncbi:9606">participants</span>
###xml 454 465 <span type="species:ncbi:9606">participant</span>
We thank the participants of the Olivetti Study, the British Genetics of Hypertension Study, the Estonian HYPEST sample collection, Whitehall 2 Study and English Longitudinal Study of Ageing, and the London Life Sciences Prospective Population Cohort, who enabled these studies. We also thank Piret Kelgo, Peeter Juhanson, Tiina Rebane, Anne Speek, Aino Hallik, and Kersti Kivi; and Drs Karel Tomberg, Mai Rosenberg, and Tiina Ristimae for assistance in participant recruitment and data collection for the Estonian HYPEST sample collection.
###end p 135
###begin title 136
Abbreviations
###end title 136
###begin p 137
body mass index
###end p 137
###begin p 138
confidence interval
###end p 138
###begin p 139
diastolic blood pressure
###end p 139
###begin p 140
###xml 0 5 <span type="species:ncbi:9606">human</span>
human embryonic kidney
###end p 140
###begin p 141
systolic blood pressure
###end p 141
###begin p 142
standard error of the mean
###end p 142
###begin title 143
References
###end title 143
###begin article-title 144
Hyperuricemia in primary and renal hypertension
###end article-title 144
###begin article-title 145
Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence
###end article-title 145
###begin article-title 146
Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers
###end article-title 146
###begin article-title 147
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey
###end article-title 147
###begin article-title 148
New insights into renal transport of urate
###end article-title 148
###begin article-title 149
The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts
###end article-title 149
###begin article-title 150
Genome-wide association study identifies novel genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia
###end article-title 150
###begin article-title 151
###xml 39 44 <span type="species:ncbi:9606">human</span>
Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking
###end article-title 151
###begin article-title 152
The Xenopus oocyte expression system for the cDNA cloning and characterization of plasma membrane transport proteins
###end article-title 152
###begin article-title 153
###xml 59 62 <span type="species:ncbi:9606">man</span>
Pharmacokinetics and biotransformation of benzbromarone in man
###end article-title 153
###begin article-title 154
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes
###end article-title 154
###begin article-title 155
Uric acid metabolism and tubular sodium handling. Results from a population-based study
###end article-title 155
###begin article-title 156
###xml 87 90 <span type="species:ncbi:9606">men</span>
Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study
###end article-title 156
###begin article-title 157
Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study
###end article-title 157
###begin article-title 158
###xml 23 28 <span type="species:ncbi:9606">human</span>
Genome-wide mapping of human loci for essential hypertension
###end article-title 158
###begin article-title 159
Allelic discrimination using fluorogenic probes and the 5' nuclease assay
###end article-title 159
###begin article-title 160
The International HapMap Project
###end article-title 160
###begin article-title 161
PLINK: a tool set for whole-genome association and population-based linkage analyses
###end article-title 161
###begin article-title 162
Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure
###end article-title 162
###begin article-title 163
Measuring inconsistency in meta-analyses
###end article-title 163
###begin article-title 164
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
The expression of GLUT8, GLUT9a, and GLUT9b in the mouse testis and sperm
###end article-title 164
###begin article-title 165
Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage
###end article-title 165
###begin article-title 166
GLUT9 is differentially expressed and targeted in the preimplantation embryo
###end article-title 166
###begin article-title 167
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout
###end article-title 167
###begin article-title 168
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects
###end article-title 168
###begin article-title 169
Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study
###end article-title 169
###begin article-title 170
Molecular identification of a renal urate anion exchanger that regulates blood urate levels
###end article-title 170
###begin article-title 171
[Physiology and biochemistry of uric acid]
###end article-title 171
###begin article-title 172
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites
###end article-title 172
###begin article-title 173
Galectin 9 is the sugar-regulated urate transporter/channel UAT
###end article-title 173
###begin article-title 174
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux
###end article-title 174
###begin article-title 175
###xml 20 25 <span type="species:ncbi:9606">human</span>
Urate transport via human PAH transporter hOAT1 and its gene structure
###end article-title 175
###begin article-title 176
A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity
###end article-title 176
###begin article-title 177
###xml 69 85 <span type="species:ncbi:562">Escherichia coli</span>
Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli
###end article-title 177
###begin article-title 178
###xml 24 27 <span type="species:ncbi:10116">rat</span>
Glucose transporters of rat proximal tubule: differential expression and subcellular distribution
###end article-title 178
###begin article-title 179
###xml 65 68 <span type="species:ncbi:10116">rat</span>
Differential localization of two glucose transporter isoforms in rat kidney
###end article-title 179
###begin article-title 180
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Presence of fructose transporter GLUT5 in the S3 proximal tubules in the rat kidney
###end article-title 180
###begin article-title 181
###xml 121 122 121 122 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose
###end article-title 181
###begin article-title 182
Renal Na(+)-glucose cotransporters
###end article-title 182
###begin article-title 183
Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting
###end article-title 183
###begin article-title 184
###xml 90 93 <span type="species:ncbi:10116">rat</span>
Contribution of intestine and kidney to glucose fluxes in different nutritional states in rat
###end article-title 184
###begin article-title 185
###xml 59 64 <span type="species:ncbi:9606">human</span>
Gluconeogenesis from glutamine and lactate in the isolated human renal proximal tubule: longitudinal heterogeneity and lack of response to adrenaline
###end article-title 185
###begin article-title 186
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us
###end article-title 186
###begin article-title 187
Plasma uric acid and the risk of type 2 diabetes in a Chinese community
###end article-title 187
###begin article-title 188
###xml 50 53 <span type="species:ncbi:9606">men</span>
Hyperuricemia and incidence of hypertension among men without metabolic syndrome
###end article-title 188
###begin article-title 189
Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third national health and nutrition examination survey
###end article-title 189
###begin article-title 190
Serum uric acid and hypertension: the Olivetti heart study
###end article-title 190
###begin p 191
paragraph sign These authors also contributed equally to this work.
###end p 191
###begin p 192
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author Contributions.</bold>
Author Contributions. M.J. Caulfield, P.B. Munroe, F.J. Charchar, K.H. Moley, and C. Cheeseman contributed to study design, execution, planning, analysis, and writing of the manuscript. D. O'Neill, K. Witkowska, M. Doblado, S. Evans, P. Howard, S. Newhouse, A. Onipinla, S. Shaw-Hawkins, R. Dobson, C. Wallace, M. Brown, J. Connell, A. Dominiczak, G.M. Lathrop, N.J. Samani, M. Marmot, E. Brunner, J. Chambers, P. Elliott, J. Kooner, M. Laan, E. Org, G. Veldre, and M. Viigimaa contributed to design and execution of the study. S. Eyheramendy, M. Farrall, M. Kumari, F. Cappuccio, C. Ji, R. Iacone, and P. Strazzullo contributed to design, execution, and analysis.
###end p 192
###begin p 193
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: The BRIGHT study and current work are supported by the Medical Research Council (MRC) of Great Britain (grant no. G9521010D) and the British Heart Foundation (grant no. PG02/128). K.H. Moley is supported by an American Diabetes Association Research Grant. S. Evans is funded by National Institutes of Health (NIH) grant no. NIH-NIDDK T32-DK07120. C. Cheeseman is funded by the Canadian Breast Cancer Foundation. The Wellcome Trust Case Control Consortium was funded by the Wellcome Trust (grant number 076113/B/04/Z). The Barts and The London Charity funded the Barts and The London Genome Centre. A. Dominiczak and N.J. Samani are British Heart Foundation Chair holders. C. Wallace is funded by the British Heart Foundation (grant no. FS/05/061/19501). The LOLIPOP Study was funded by the British Heart Foundation. The HYPEST sample collection was financed by Wellcome Trust International Senior Research Fellowship to M. Laan (grant no. 070191/Z/03/Z) in Biomedical Science in Central Europe and by Estonian Ministry of Education and Science core grant no. 0182721s06. M. Marmot is supported by an MRC Research Professorship. The Whitehall II study has been supported by grants from the UK: MRC; Economic and Social Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; National Heart Lung and Blood Institute (grant no. HL36310); and from the US: NIH, National Institute on Aging (NIA; grant no. AG13196); NIH, Agency for Health Care Policy Research (grant no. HS06516); and the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health. Samples from the English Longitudinal Study of Ageing (ELSA) DNA Repository (EDNAR), received support under a grant (AG1764406S1) awarded by the NIA. ELSA was developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected by the National Centre for Social Research. The developers and funders of ELSA and the Archive do not bear any responsibility for these analyses or interpretations presented here. The funders of this work did not take part in study design, data collection, or analysis of these data. In addition, none of the funders took part in the decision to publish, or in the preparation of this manuscript.
###end p 193
###begin p 194
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 194

